Journal Mobile Options
Table of Contents
Vol. 57, No. 1-2, 2008
Issue release date: June 2008
Section title: Original Paper
Neuropsychobiology 2008;57:80–87
(DOI:10.1159/000135641)

Typical and Atypical Antipsychotics – The Misleading Dichotomy

Results from the Working Group ‘Drugs in Psychiatry’ (AGATE)

Fischer-Barnicol D. · Lanquillon S. · Haen E. · Zöfel P. · Koch H.J. · Dose M. · Klein H.E.
aUniversity Hospital for Psychiatry and Psychotherapy, Regensburg, bHospital for Psychiatry and Psychotherapy, Taufkirchen, cComputing Center of the Institute for Bioinformatics, University of Marburg, Marburg, and dHospital for Psychiatry and Psychotherapy, Helios Klinikum, Aue, Germany

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 9/19/2007
Accepted: 2/15/2008
Published online: 6/2/2008

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 4

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: http://www.karger.com/NPS

Abstract

Objectives: (1) To investigate the risk of extrapyramidal motor side effects (EPS) associated with the prescription of different antipsychotics under naturalistic treatment conditions; (2) to test the rationale of the terms ‘typical’ and ‘atypical’ based on EPS rates. Design: Cross-sectional study in the federal state of Bavaria. Setting: 20 psychiatric hospitals in Bavaria. Participants: 6,061 inpatients, aged 18–65 years, with psychotic disorders. Main Outcome Measures: Co-medication with the anticholinergic biperiden was used as an index of EPS. Odds ratios for EPS and numbers needed to harm [number of patients who would need to be treated to obtain one more case with an adverse outcome (i.e. EPS) as compared with the control treatment (clozapine)] were calculated to obtain risk estimates for 15 different antipsychotics. Results: Groups of ‘typical’ and ‘atypical’ antipsychotics were not homogeneous in their EPS rates, and showed wide variation within each group. Nor did the frequency of EPS allow a clear distinction between the groups. There were 2 reasons for this: first, EPS rates rose continuously over the whole spectrum of drugs under study, and therefore precluded the definition of a cut-off score; second, there was considerable overlap between the 2 groups as EPS rates of various ‘atypicals’ (e.g. amisulpride, risperidone and zotepine) did not differ from some ‘typical’ substances (e.g. fluphenazine), while one ‘typical’ antipsychotic (perazine) even had a lower EPS risk than most ‘atypicals’. Conclusions: The odds of inducing EPS are not distinguishable between ‘typical’ and ‘atypical’ antipsychotics as EPS rates rise on a continuous scale throughout both classes. We propose dropping the categorization of antipsychotics as ‘typical’ and ‘atypical’ and instead using risk estimates like number needed to harm for EPS to help in benefit/risk considerations for antipsychotic treatment.


  

Author Contacts

Dr. Horst J. Koch, MFPM, DCPSA
Klinik für Psychiatrie und Psychotherapie
Gartenstrasse 6
DE–08280 Aue (Germany)
Tel. +49 3771 58 1509, Fax +49 3771 58 1429, E-Mail horst.koch@helios-kliniken.de

  

Article Information

D.F.-B. and S.L. contributed equally to this paper.

Received: September 19, 2007
Accepted after revision: February 15, 2008
Published online: June 2, 2008
Number of Print Pages : 8
Number of Figures : 2, Number of Tables : 4, Number of References : 45

  

Publication Details

Neuropsychobiology (International Journal of Experimental and Clinical Research in Biological Psychiatry, Pharmacopsychiatry, Biological Psychology/Pharmacopsychology and Pharmacoelectroencephalography)

Vol. 57, No. 1-2, Year 2008 (Cover Date: June 2008)

Journal Editor: Strik W. (Bern)
ISSN: 0302–282X (Print), eISSN: 1423–0224 (Online)

For additional information: http://www.karger.com/NPS


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 9/19/2007
Accepted: 2/15/2008
Published online: 6/2/2008

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 4

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: http://www.karger.com/NPS


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.